ADXN
What one share of Addex Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises of a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed by our partner and internally.
Addex Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.00 |
|---|---|
| Profit | −$0.45 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.15 |
| Cash and investments | $0.08 |
| Debt | $0.00 |
| Book value | $0.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$1.55 | $0.00 | −$1.01 | — | $0.62 |
| 2018 | $1.59 | −$0.43 | $0.00 | $0.46 | — | $9.07 |
| 2019 | $0.63 | −$3.38 | $0.01 | −$2.17 | — | $5.95 |
| 2020 | $0.87 | −$3.08 | $0.01 | −$2.93 | — | $3.66 |
| 2021 | $0.56 | −$2.95 | $0.01 | −$2.83 | — | $2.93 |
| 2022 | $0.20 | −$2.90 | $0.00 | −$2.29 | — | $0.41 |
| 2023 | $0.15 | −$0.95 | $0.00 | −$0.72 | — | $0.07 |
| 2024 | $0.03 | $0.49 | $0.00 | −$0.37 | — | $0.50 |
| 2025 | $0.00 | −$0.45 | $0.00 | −$0.15 | — | $0.24 |